Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 4, Pages 998
Publisher
MDPI AG
Online
2020-04-17
DOI
10.3390/cells9040998
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
- (2019) Bryan D. Choi et al. Journal for ImmunoTherapy of Cancer
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- In vitro immunotherapy potency assays using real-time cell analysis
- (2018) Fabio Cerignoli et al. PLoS One
- Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells
- (2018) TOSHIHARU MURAKAMI et al. ANTICANCER RESEARCH
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
- (2018) Xingliang Guo et al. Frontiers in Pharmacology
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
- (2016) S. Shiina et al. Cancer Immunology Research
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2016) Shu Su et al. Scientific Reports
- Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
- (2015) S Kuramitsu et al. CANCER GENE THERAPY
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
- (2015) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
- (2015) Naoyuki Sakamoto et al. Journal of Translational Medicine
- EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
- (2015) Nina Struve et al. Oncotarget
- Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
- (2015) Emily Padfield et al. Frontiers in Oncology
- Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting
- (2014) Jiankui Zhou et al. FEBS Journal
- An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells
- (2014) Janet Kerstin Peper et al. JOURNAL OF IMMUNOLOGICAL METHODS
- LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
- (2013) J. T. Yeung et al. CLINICAL CANCER RESEARCH
- Cas9 as a versatile tool for engineering biology
- (2013) Prashant Mali et al. NATURE METHODS
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts
- (2013) Masasuke Ohno et al. Journal for ImmunoTherapy of Cancer
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
- (2012) Courtney L. Erskine et al. Jove-Journal of Visualized Experiments
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
- (2011) A. L. Rivera et al. NEURO-ONCOLOGY
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen
- (2010) Masasuke Ohno et al. CANCER SCIENCE
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGF receptor variant III as a target antigen for tumor immunotherapy
- (2008) Gordon Li et al. Expert Review of Vaccines
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now